Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Highlights of primary prevention of death in patients with ventricular arrhythmias (VA) are discussed. Overview of all main clinical trials exploring various anti-arrhythmic drugs in prevention of death in patients with VA is presented. It is emphasized that in patients with organic heart disease and VA only beta-blockers and amiodarone are able to reduce mortality, while other drugs have no effect on mortality, or they even increase mortality mainly due to arrhythmogenic effect. Recent clinical studies of the cardioverter-defibrillators efficacy in these patients are present￾ed. It is shown that the use of cardioverter defibrillators compared with pharmacotherapy is more effective in prevention of fatal outcomes.

About the Author

Yu. A. Bunin
Russian Medical Academy of Postgraduate Education
Russian Federation
Barrikadnaya ul. 2/1, Moscow, 123995


1. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2006; 8(9): 746-837.

2. Cardiac arrhythmia suppression trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321(6): 406-412.

3. Effect ofthe antiarrhythmic agent moricizine on survival after myocardial infarction. The cardiac arrhythmia suppression trial II investigators. N Engl J Med 1992; 327(4): 227-233.

4. Morganroth J., Goin J.E. Qinidine-related mortality in the short-to-medium term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991; 84(5): 1977-1983.

5. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993; 270(13): 1589-1595.

6. Antman E.M. ST-elevation myocardial infarction: management. In: Braunwald E., Zipes L., Libby P., Bonow R (eds). Heart disease. Philadelphia: W.B. Saunders company; 2005. p.1167-1226.

7. Gottlieb S.S., MacCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and lowrisk patients after myocardial infarction. N Engl J Med 1998; 339(8): 489-497.

8. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247(12):1707-1714.

9. Freemantle N., Cleland J.G., Yoyng P. et al. Beta-blockade after myocardial infarction: systematic reviw and meta regression analysis. BMJ 1999; 318(7200): 1730-1737.

10. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004; 110(5): 588-636.

11. DargieH.J. Effect carvediol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357(9266): 1385-1390.

12. Cairns J.A., Connoly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent orrepetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349(9053): 675-682.

13. Julian D.G., Camm A.F., Frangin G. et al. Randomised trial of effect of amiodarone on mortality in patientswith left-ventricular dysfunction afterrecent myocardial infarction: EMIAT. Lancet1997;349(9053): 667-674.

14. Singh S.N., Fletcher R.D., Fisher S.G. et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995; 333(2): 77-82.

15. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350(9089): 1417-1424.

16. Doval H.C., Nul D.R., Grancelli H.O. et al. Nonsustained ventricular tachycardia in severe heart failure. Independent markers of increased mortality due to sudden death. GESICA-GEMA investigators. Circulation 1996; 94(12): 3198-3203.

17. Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352(3): 225-237.

18. Thomas K.L., Al-Khatib S.M., Lokhnygina Y. et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. Am Heart J 2008; 155(1): 87-93.

19. PicciniJ.P., BergerJ.S., O'Connor C.M. Amiodarone forthe prevention of sudden cardiac death: a meta￾analysis of randomized controlled trials. Eur Heart J 2009;30(10):1245-53.

20. Boutitie F. BoisselJ-P., Connolly S.J. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial InfarctAmiodarone Trial) and CAMIAT (CanadianAmiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99(17): 2268- 2275.

21. JulianD.G., Prescott R.J.,Jackson F.S., Szekely D. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1(8282): 1142-1147.

22. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 2000; 15(1): 41- 53.

23. Kober L., Torp-Pedersen C., McMurray J.J. et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358(25): 2678-2687.

24. Hohnloser S.H. Crijns H.J., van Eickels M. Effect of dropedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360(7): 668-678.

25. Moss A.J., Hall W.J., Cannom D.S. et al. Improved survival with an implanted defibrillator in patients with coronary disease an high risk for ventricular arrhythmia. N Engl J Med 1996; 335(26): 1933- 1940.

26. Buxton A.E., Lee K.L., Fisher J.D. et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341(25): 1882-1890.

27. Moss A.J., Zareba W., Hall W.J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877-883.

28. Bigger J.T. Jr. Prophylactic use implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337(22): 1569-1575.

29. Hohnloser S.H., Kuck K.H., Dorian P. et al. Prophylactic use of an implantation cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351(24): 2481-2488.

30. Nanthakumar K., Epstein A.E., Kay G.N. et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction.J Am Coll Cardiol 2004; 44(11): 2166-2172.

31. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnotmalities. Circulation 2008; 117(21): e350-e408.

For citation:


Views: 348

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)